Drug Profile
AIC 284
Alternative Names: AIC284; BAY-504798; IL2-mutein - AiCuris; Interleukin-2-mutein - AiCurisLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Bayer
- Developer AiCuris; Bayer
- Class Antineoplastics; Interleukins
- Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Autoimmune disorders
- Discontinued Cancer; HIV infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Autoimmune-disorders in Germany (Parenteral)
- 25 Jan 2016 AIC 284 is available for licensing as of 25 Jan 2016. http://www.aicuris.com/
- 25 Jan 2016 Phase-I clinical trials in Autoimmune disorders in Germany (Parenteral) (AiCuris pipeline; January 2016)